Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 6
Submit an article Journal homepage
118
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma

Brian T. Hilla Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8781-3327View further author information
ORCID Icon,
Yanwen Chenb Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USAORCID Iconhttps://orcid.org/0000-0003-3147-0278View further author information
ORCID Icon,
Deepa Jagadeesha Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USAORCID Iconhttps://orcid.org/0000-0002-1772-0659View further author information
ORCID Icon,
Robert Deana Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USAORCID Iconhttps://orcid.org/0000-0003-2559-563XView further author information
ORCID Icon,
Omer Koca Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USAView further author information
,
Kirsten Boughanc Case Western Reserve University School of Medicine, University Hospitals, Cleveland, OH, USAView further author information
,
Brenda Cooperc Case Western Reserve University School of Medicine, University Hospitals, Cleveland, OH, USAORCID Iconhttps://orcid.org/0000-0001-9376-9377View further author information
ORCID Icon,
Brad Pohlmana Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USAView further author information
,
Paolo Caimia Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USAORCID Iconhttps://orcid.org/0000-0003-1436-0464View further author information
ORCID Icon &
Mitchell R. Smitha Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;d The Follicular Lymphoma Foundation, Washington, DC, USAORCID Iconhttps://orcid.org/0000-0003-1428-8765View further author information
ORCID Icon show all
Pages 768-773 | Received 22 Sep 2023, Accepted 26 Feb 2024, Published online: 08 Mar 2024

References

  • Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10(7):74. doi:10.1038/s41408-020-00340-z
  • Nastoupil LJ, Sinha R, Byrtek M, et al. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol. 2016;172(5):724–734. doi:10.1111/bjh.13895
  • Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265. doi:10.1182/blood-2003-12-4434
  • Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–1122. doi:10.1016/S1470-2045(15)00169-2
  • Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–4562. doi:10.1200/JCO.2008.21.3991
  • Leonard JP, Trneny M, Izutsu K, et al. First-Line treatment of patients with indolent Non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-Year follow-up study. J Clin Oncol. 2019;37(14):1188–1199. doi:10.1200/JCO.18.00605
  • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210. doi:10.1016/S0140-6736(12)61763-2
  • Chong EA, Ahmadi T, Aqui NA, et al. Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015;21(8):1835–1842. doi:10.1158/1078-0432.CCR-14-2221
  • Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (alliance). J Clin Oncol. 2015;33(31):3635–3640. doi:10.1200/JCO.2014.59.9258
  • Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014;165(3):375–381. doi:10.1111/bjh.12755
  • Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188–1199. doi:10.1200/JCO.19.00010
  • Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934–947. doi:10.1056/NEJMoa1805104
  • Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the alliance for clinical trials in oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4(4):e176–e182. doi:10.1016/S2352-3026(17)30028-5
  • Blum KA, Polley MY, Jung SH, et al. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (alliance). Cancer. 2019;125(19):3378–3389. doi:10.1002/cncr.32289
  • Evens AM, Hong F, Habermann TM, et al. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clin Cancer Res. 2020;26(17):4468-4477.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.